NCT01024517View on ClinicalTrials.gov

GLPG0259 Solid Formulation Bioavailability and Food Effect

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

February 28, 2010

Conditions
Healthy
Interventions
DRUG

GLPG0259 solution

single oral dose, GLPG0259, 50 mg oral solution

DRUG

GLPG0259

single oral dose, GLPG0259, 50 mg solid formulation

Trial Locations (1)

Unknown

SGS Stuivenberg, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY